News
Ulcerative colitis and diabetes generics launched in US
Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 9 July 2018 that it had launched generic budesonide extended-release tablets (9 mg) in the US. Then on 25 July 2018, Sun Pharmaceutical Industries (Sun Pharma), one of India’s largest pharmaceutical manufacturers, announced that it had launched generic metformin extended-release tablets (500 and 1,000 mg) in the US.
Generic cancer pain relief launched in Japan
Japan-based Daiichi Sankyo announced on 15 June 2018 that it had launched a generic version of cancer pain relief Fentos Tape (fentanyl citrate tape).
FDA approves first Suboxone generics for opioid dependence
The US Food and Drug Administration (FDA) announced on 14 June 2018 that it had approved the first generics of Suboxone (buprenorphine/naloxone) sublingual film (applied under the tongue) for the treatment of opioid dependence. The generics have been developed by Indian generics maker Dr Reddy’s Laboratories (Dr Reddy’s) and US-based drugmaker Mylan.
US approval for prostate cancer formulation and impotence generics
The US Food and Drug Administration (FDA) has approved generics of tadalafil, used to treat male impotence, and a new abiraterone formulation, a treatment for prostate cancer.
Aurobindo and Lannett expand their generics portfolios
Both Indian generics maker Aurobindo Pharma (Aurobindo) and US generics company Lannett have announced efforts to increase their generics portfolios.
Price of leukaemia drug in Japan halved
Japanese drugmaker Ohara Pharmaceutical has reduced the price of its leukaemia generic imatinib to about half the price of the generics sold by its competitors to encourage leukaemia patients to use more affordable medication.
Hikma launches HIV generic ritonavir in the US
Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) announced on 20 March 2018 that its wholly owned US subsidiary West-Ward Pharmaceuticals Corp had launched generic ritonavir tablets (100 mg) in the US.
Alvogen receives European approval for generic lenalidomide
US generics company Alvogen announced on 24 April 2018 that it had successfully concluded multiple registration procedures for its lenalidomide generic capsules.
Teva launches ulcerative colitis generic in the US
Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 26 March 2018 that it had launched generic mesalamine delayed-release tablets (1.2 g) in the US.
Australia’s Mayne Pharma launches generic antibiotic in US
Australia-based Mayne Pharma announced on 15 March 2018 that it had launched a generic version of doxycycline monohydrate immediate release (IR) capsules (50, 75 and 100 mg) in the US.
Generics News Research General
- Approving generics of polymer-based parenteral...Generics/Research | Posted 26/02/2021
- AIFA updates the Transparency Lists for genericsGenerics/General | Posted 26/02/2021
- Adherence improves long-term prognosis and medi...Generics/Research | Posted 19/02/2021
- Anti-competitive strategic patenting by pharmac...Generics/Research | Posted 12/02/2021
Biosimilars News Research General
- Biosimilar approvals and launches in the USBiosimilars/General | Posted 26/02/2021
- Biosimilars approved in AustraliaBiosimilars/General | Posted 21/02/2014
- Biosimilar approvals and patent litigation in t...Biosimilars/General | Posted 19/02/2021
- Collaboration between regulatory authorities fo...Biosimilars/Research | Posted 26/02/2021